Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZEPIZURE
- Development stage
- Preclinical
- Lead developer
- Crossject
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
ZEPIZURE is an emergency treatment for epileptic seizures, particularly status epilepticus, developed by Crossject. It consists of midazolam delivered via the ZENEO® needle-free auto-injector platform. This innovative delivery system allows for rapid, intramuscular administration by patients or untrained caregivers, even through clothing, aiming to provide faster and more consistent absorption of midazolam compared to traditional methods like intranasal administration. The drug is designed to quickly suppress seizures by enhancing inhibitory neurotransmission in the brain.
- Brand names
- ZEPIZUREZEPIZURE Junior
- Other names
- midazolamZENEO midazolam
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on ZEPIZURE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZEPIZURE.